Breast Cancer Medications

5 · 10mg

developed to target cancer cells to support tumour growth suppression.

1mg

The product is utilized to alleviate hormonal signals influencing tissue growth in specific patient populations.

1mg

Arimidex is developed to target hormone-dependent breast cancer and is formulated to alleviate tumour progression.

1mg

Indicated to help manage oestrogen-dependent conditions by supporting the suppression of excess hormone production in postmenopausal patients.

25mg

Developed to target oestrogen production and indicated to support cancer treatment, this inhibitor is utilized to address hormone-sensitive malignancies.

500mg

Utilized to target malignant cell proliferation, this chemotherapy agent is indicated to support the management of advanced colorectal, breast, and gastric carcinomas.

500mg

Developed to target cancerous growths by utilizing systemic conversion to therapeutic agents that inhibit DNA synthesis.

2.5mg

Femara is indicated for the treatment of hormone-dependent breast cancer and utilized to alleviate tumour growth in post-menopausal women.

10 · 20mg

formulated to manage hormone-receptor-positive breast cancer and to support treatment outcomes through oestrogen receptor inhibition.

10 · 20mg

Indicated to support to mitigate breast cancer progression, utilized in patients requiring hormonal manipulation for effective disease management.